These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 15080292

  • 1. New biologic therapies for psoriatic disease.
    Bohjanen KA, Prawer SE.
    Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM, Saini R, Tutrone WD.
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A.
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [Abstract] [Full Text] [Related]

  • 5. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM.
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [Abstract] [Full Text] [Related]

  • 6. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
    Graves JE, Nunley K, Heffernan MP.
    J Am Acad Dermatol; 2007 Jan; 56(1):e55-79. PubMed ID: 17190618
    [Abstract] [Full Text] [Related]

  • 7. Systemic therapies for psoriasis: understanding current and newly emerging therapies.
    Sobell JM, Hallas SJ.
    Semin Cutan Med Surg; 2003 Sep; 22(3):187-95. PubMed ID: 14649586
    [Abstract] [Full Text] [Related]

  • 8. Biologic therapies for psoriasis. A systematic review.
    Boehncke WH, Prinz J, Gottlieb AB.
    J Rheumatol; 2006 Jul; 33(7):1447-51. PubMed ID: 16724367
    [Abstract] [Full Text] [Related]

  • 9. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.
    Young MS, Horn EJ, Cather JC.
    Expert Rev Clin Immunol; 2011 Jan; 7(1):9-13. PubMed ID: 21162644
    [Abstract] [Full Text] [Related]

  • 10. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG, Gupta AK, Cherman AM, Inniss KA.
    J Cutan Med Surg; 2007 Jan; 11(3):99-122. PubMed ID: 17511926
    [Abstract] [Full Text] [Related]

  • 11. Immunobiologics in the treatment of psoriasis.
    Chong BF, Wong HK.
    Clin Immunol; 2007 May; 123(2):129-38. PubMed ID: 17317321
    [Abstract] [Full Text] [Related]

  • 12. Update on the mechanisms and efficacy of biological therapies for psoriasis.
    Koo J, Khera P.
    J Dermatol Sci; 2005 May; 38(2):75-87. PubMed ID: 15862940
    [Abstract] [Full Text] [Related]

  • 13. Understanding the new clinical landscape for psoriasis: a comparative review of biologics.
    Sauder DN, Mamelak AJ.
    J Cutan Med Surg; 2004 May; 8(4):205-12. PubMed ID: 16091996
    [Abstract] [Full Text] [Related]

  • 14. [Biological treatment of psoriasis and psoriatic arthritis].
    Kragballe K, Deleuran B.
    Ugeskr Laeger; 2008 Jun 09; 170(24):2148-50. PubMed ID: 18565300
    [Abstract] [Full Text] [Related]

  • 15. Immunologic targets in psoriasis.
    Kupper TS.
    N Engl J Med; 2003 Nov 20; 349(21):1987-90. PubMed ID: 14627782
    [No Abstract] [Full Text] [Related]

  • 16. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.
    Tutrone WD, Saini R, Weinberg JM.
    IDrugs; 2004 Jan 20; 7(1):45-9. PubMed ID: 14730466
    [Abstract] [Full Text] [Related]

  • 17. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
    Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP.
    Ned Tijdschr Geneeskd; 2006 May 13; 150(19):1065-70. PubMed ID: 16733982
    [Abstract] [Full Text] [Related]

  • 18. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
    Montesu MA, Addis GM, Satta R, Cottoni F.
    G Ital Dermatol Venereol; 2011 Aug 13; 146(4):273-81. PubMed ID: 21785393
    [Abstract] [Full Text] [Related]

  • 19. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM, Saini R.
    Cutis; 2003 Jan 13; 71(1):25-9. PubMed ID: 12553627
    [Abstract] [Full Text] [Related]

  • 20. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ, Bello-Quintero CE.
    J Manag Care Pharm; 2004 Jan 13; 10(4):318-25. PubMed ID: 15298530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.